Danwang Medical
Shanghai
About Danwang Medical
Danwang Medical provides clinical transformation technology services to regenerative medicine for disease diagnosis and treatments. They also provide organoid drug sensitivity testing, organoid disease models, organoid drug development, and organoid chips. Danwang Medical is committed to applying the most recent clinical transformation technology of regenerative medicine to disease diagnosis and treatment, new drug screening, tumor marker development and identification, and other areas in order to provide clinical personalized treatment technology and accurate, efficient, and high-quality organoids Model to new drug research and development enterprises.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $18.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2021)
- Website: d1med.com
- Phone: 86-021-69106895
Industries & Categories
Biopharma, Biotechnology, Medical, Product Research
Canonical: https://fsome.com/organization/danwang-medical-73272 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.